Showing results (61-70 of 87) with videos related to

Sort By:
Pageof 9
American Journal of Obstetrics and Gynecology|April 1, 1996
Evaluation of a deoxyribonucleic acid probe for the detection of Trichomonas vaginalis in vaginal secretionsL R DeMeo, D L Draper, J A McGregor, et al.
JAMA|June 21, 2001
Enzyme replacement therapy in Fabry disease: a randomized controlled trialR Schiffmann, J B Kopp, H A Austin, et al.
Neurology|March 29, 2001
Evidence for neuroaxonal injury in patients with proteolipid protein gene mutationsS Bonavita, R Schiffmann, D F Moore, et al.
American Journal of Rhinology|January 1, 1997
Follow-up of University of Virginia experience with the modified Lothrop procedureC W Gross, G C Zachmann, D G Becker, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 1, 1994
Phase II trial of edatrexate in patients with advanced hepatocellular carcinomaR Pazdur, D F Moore, B Bready, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))|January 1, 1995
Cyclosporin plus doxorubicin, vincristine and etoposide in the treatment of refractory non-Hodgkin's lymphoma: a phase II studyD F Moore, F Swan, J Yau, et al.
Leukemia & Lymphoma|August 26, 1998
Phase II study of mitoguazone, cyclophosphamide, doxorubicin, vincristine and prednisone for patients with diffuse histologic subtypes of non-Hodgkin's lymphoma: an Eastern Cooperative Oncology Group Study (PE481)P H Wiernik, D F Moore, J M Bennett, et al.
Prostate Cancer and Prostatic Diseases|June 24, 2015
Primary radiotherapy vs conservative management for localized prostate cancer--a population-based studyG L Lu-Yao, S Kim, D F Moore, et al.
Brain : a Journal of Neurology|November 16, 2006
Neuropathic and cerebrovascular correlates of hearing loss in Fabry diseaseM Ries, H J Kim, C K Zalewski, et al.
Investigational New Drugs|January 1, 1994
A phase II trial of oral etoposide with mitoxantrone and ifosfamide/mesna consolidated with intravenous etoposide, methylprednisolone, high-dose arabinoside, and cisplatin as salvage therapy for relapsing and/or refractory lymphomasJ E Romaguera, M A Rodriguez, F B Hagemeister, et al.
Pageof 9